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Introduction: Thymic carcinoma is a rare and aggressive thymic 
neoplasm. The European Society of Thoracic Surgeons developed a 
retrospective database collecting patients undergoing resection for 
thymic tumors from 1990 to 2010.
Methods: Of 2265 patients with thymic tumors, there were 229 thymic 
carcinomas. Clinicopathological characteristics were analyzed includ-
ing age, associated paraneoplastic diseases, stage  (Masaoka-Koga), 
World Health Organization histologic subtypes, type of resection (total/
subtotal/biopsy/no resection), tumor size, pre/postoperative treatments, 
and recurrence. Outcome measures included overall survival (OS), 
freedom from recurrence, and cumulative incidence of recurrence.
Results: A complete resection was achieved in 140 patients (69%). 
Recurrence occurred in 54 patients (28%). Five- and 10-year OS 
rates were 0.61 and 0.37. Five- and 10-year freedom from recur-
rence rates were 0.60 and 0.43. Cumulative incidence of recurrence 
was 0.21 (3 yr), 0.27 (5 yr), and 0.32 (10 yr). Survival was better 
after surgical resection versus biopsy/no resection (p < 0.001), after 
complete resection versus subtotal resection (p < 0.001), and when 
using Masaoka-Koga system (stages I–II versus III versus IV) (p < 
0.001). The use of multidisciplinary treatments resulted in a survival 
advantage which was significant in the surgery + radiotherapy group 
(p = 0.02). Incomplete resection (p < 0.0001) and advanced stage 
(Masaoka-Koga III–IV) (p = 0.02) had a negative impact on OS at 
multivariable analysis. Administration of adjuvant radiotherapy was 
beneficial in increasing OS (p = 0.02).
Conclusions: The results of our study indicate that patients with 
thymic carcinoma should undertake surgical resection whenever 
possible; a complete resection and early Masaoka-Koga stage are 
independent predictors of improved survival; our results also suggest 
that postoperative radiotherapy is beneficial in improving survival.
Key Words: Thymic carcinoma, Staging, Prognostic factors, Thymic 
tumors, Surgery.
(J Thorac Oncol. 2014;9: 541–548)
Thymic tumors are rare neoplasms, although they rep-resent the most frequent anterior mediastinal tumors. 
According to the latest World Health Organization (WHO) 
histologic classification, thymic tumors are divided in thy-
momas and thymic carcinomas, the latter including the rare 
neuroendocrine thymic tumors (NETTs). The distinction 
between thymomas and thymic carcinomas reflects a differ-
ent histologic and molecular pattern and a different clinical 
and prognostic behavior. Thymic carcinomas usually present 
with locally advanced stages, an aggressive behavior, and a 
frequent incidence of lymphatic or distant metastases. As a 
consequence, survival rates are lower than those observed in 
thymomas.1–3
Due to the rarity of these tumors, only small series have 
been published so far on thymic carcinomas, with conflicting 
results about the prognostic factors and optimal management.
The last decade has witnessed a dramatic increase of the 
interest in thymic malignancies, culminated with the creation 
of several thymic interest groups, and the foundation of the 
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International Thymic Malignancies Interest Group (ITMIG) 
in 2010.
The European Society of Thoracic Surgeons (ESTS) 
thymic working group developed a retrospective database 
among interested centers to collect patients operated on for 
thymic tumors from 1990 to 2010. The aim of this study was 
to investigate the population of patients with thymic carcino-
mas submitted to surgical resection using the ESTS retrospec-
tive thymic database, to identify possible prognostic factors 
and to evaluate optimal therapeutic strategies.
MATERIALS AND METHODS
The ESTS enquired among its members about participa-
tion to the ESTS retrospective database thymoma project to 
collect patients with thymic malignancies submitted to sur-
gery from 1990 to 2010. Follow-up data were collected until 
December 2011. Overall, 36 institutions replied, including 28 
from Europe, five from United States/Canada, and three from 
Asia (Appendix 2). Institutional review board approval was 
obtained at each institution.
Of 2265 patients with thymic malignancies, 229 thy-
mic carcinomas were identified. NETTs were excluded. 
Recording variables in the data set included demographics, 
the presence of associated paraneoplastic syndromes, his-
tology, 2004 WHO classification,4 tumor size measured as 
the largest diameter on the surgical specimen, tumor stag-
ing according to  Masaoka-Koga,5 completeness of resection, 
administration of preoperative (primary) or postoperative 
(adjuvant) treatment, type of surgical procedure, cause of 
death (when available), and recurrence. Clinical (preopera-
tive) staging was assessed in all cases by computed tomogra-
phy scan, integrated by magnetic resonance imaging to assess 
great vessel invasion in selected patients. Integrated positron 
emission  tomography (PET)-computed tomography (CT) was 
used by most centers to exclude distant metastases. No cen-
ter employed tumor, node, metastasis (TNM)-based staging 
systems. We had no sufficient information about the nodal 
status and the site of distant metastases to draw any conclu-
sion about their role as prognostic factors. Patients operated 
on before 2004 were reclassified at each center using the lat-
est WHO histologic classification. Histologic specimens were 
assessed in each center by pathologists experienced in thymic 
malignancies, and the differential diagnosis between thymic 
carcinoma/thymoma/lung cancer was performed in each cen-
ter based on morphological evaluation and using immunohis-
tochemistry (CD5 and KIT staining) when indicated.
Study outcomes included overall survival (OS), free-
dom from recurrence (FFR), and the cumulative incidence of 
recurrence (CIR). OS was computed from the date of surgery 
to the date of death (any cause). FFR was computed from 
the date of surgery to the date of recurrence or death (any 
cause). CIR was calculated from the date of surgery to the 
date of recurrence. Death from any cause was considered as 
a competing event in FFR analysis.6 Patients alive or without 
recurrence were censored on the date of the last follow-up. OS 
was calculated on the entire population, whereas FFR and CIR 
were evaluated in patients receiving a complete (R0) resection 
and complete information on recurrence status.
Statistical Analysis
The Kaplan–Meier product-limit method was used to 
compute OS and FFR. The log-rank test was used to assess 
the differences between survival rates. The Nelson–Aalen 
method was used to calculate the CIR. Univariable and mul-
tivariable Cox proportional hazard models with shared frailty 
were employed to evaluate OS prognostic factors. Evaluated 
predictors included age at surgery (as continuous), sex, 
 Masaoka-Koga stage (I–II versus III–IV), tumor size (as con-
tinuous), histology (squamous cell versus other subtypes), 
resection status (complete/incomplete), associated Myasthenia 
Gravis (MG), and administration of primary (preoperative) and 
adjuvant (postoperative) treatment. FFR analysis was under-
taken using competing-risks regression models (Fine and Gray 
method), taking into account death by any causes as competing 
event. The missing data in the different analyses were multiple 
imputed; 10 imputed data sets provided the combined esti-
mates. Chi-square test and Fisher’s exact test, when appropri-
ate, were used to evaluate the differences between groups. The 
statistical analysis was performed using STATA (version 12.1; 
StataCorp LP, College Station, TX).
RESULTS
The median contribution by institution was four patients 
(range, 1–28); 23 institutions (68%) provided less than five 
patients, seven institutions (21%) provided six to 15 patients, 
and four institutions (11%) contributed with more than 15 
patients.
Median follow-up time was 44 months (interquartile 
range [IQR], 67 mo; range, 2-214).
Follow-up data were complete in 73% of the patients at 
the end of the follow-up period (December 31, 2011).
Figure 1 illustrates the flow of patients according to the 
different end points. Two hundred fifteen patients were avail-
able for OS analysis; FFR and recurrence analysis could be 
performed on 113 patients.
Clinical Data
The characteristics of the cohort population (n = 229) 
are illustrated in Table 1. Median age at surgery was 58 
years, ranging from 22 to 88 years, and 58% of the patients 
(133 of 229) were men. Associated MG was observed in 31 
of 229 patients (14%). The most frequent histologic subtypes 
were squamous cell carcinoma (98 of 129 patients, 76%), fol-
lowed by mucoepidermoid type (10 patients, 8%). Median 
tumor size at surgery (largest diameter) was 5 cm (range, 
1–25 cm). According to resection status, a complete (macro 
and microscopic) resection (R0) was achieved in 140 of 203 
patients (69%); an incomplete resection was performed in 47 
patients, of whom there were 23 microscopic (R1) and 24 mac-
roscopic (R2) residuals; 16 patients received only biopsy (no 
resection). According to Masaoka-Koga stage, the majority of 
patients were at advanced stages (stages III–IV, 132 of 186, 
71%). One-third of the patients (78 of 215) received preopera-
tive (primary) therapy, mostly chemotherapy, including four 
patients stage I, three patients stage IIa, six patients stage IIb, 
31 patients stage III, 15 patients stage IVa, and five patients 
stage IVb (14 patients with missing information). Indications 
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to preoperative therapy depended on each center’s experience, 
although it was more frequently employed in more advanced 
stages and when a complete resection could not be anticipated 
at preoperative clinical evaluation. Adjuvant therapy after 
surgery was employed in 69% of the patients (149 of 215), 
including 16 patients stage I, six patients stage IIa, 11 patients 
stage IIb, 58 patients stage III, 20 patients stage IVa, and nine 
patients stage IVb (29 patients with missing information). 
Indications to adjuvant therapy also depended on each cen-
ter’s experience, although there were no differences between 
early and advanced stages (p = 0.27) and between R0 and R+ 
patients (p = 0.45). The most frequent type of adjuvant ther-
apy was radiation therapy, either alone (n = 59) or combined 
with chemotherapy (n = 72). Resectability rates were found 
to be lower in squamous cells carcinoma (78% versus 81%, 
p = 0.06), and they decreased with stage (I 91%; IIa 62%; IIb 
74; III 66%, IVa 28%; IVb 19%).
Survival Analysis
At the end of the study period, 92 patients died. Of these, 
37 died from tumor-related causes. Fifty-four patients (28%) 
experienced a recurrence at follow-up. In 47 cases, location 
of recurrence was assessed, including 24 local/regional (12 
pleura, eight mediastinum, two lymphnodes, and two locore-
gional not otherwise specified [NOS]) and 23 distant (12 lung, 
three liver, three bones, and five distant NOS) recurrences.
The 3-year, 5-year, and 10-year overall OS rates were 
0.72 (95% confidence interval [CI], 0.65–0.78), 0.61 (95% CI, 
0.54–0.68), and 0.37 (95% CI, 0.29–0.47). The 3-year, 5-year 
and 10-year overall FFR rates were 0.71 (95% CI, 0.61–0.79), 
0.60 (95% CI, 0.49–0.69), and 0.43 (95% CI, 0.31–0.55). CIR 
was 0.21 (95% CI, 0.14–0.30) at 3 years, 0.27 (95% CI, 0.19–0.37) 
at 5 years, and 0.32 (95% CI, 0.23–0.45) at 10 years 
(Fig. 2A). It shows a steep increase in the first 5 years, fol-
lowed by a slower increase up to 10 years and a trend to a 
plateau after 10 years.
FIGURE 1.  Study flow diagram of the patient population.
TABLE 1.  Characteristics of the Patient Population
n % Median
Sex (male) 133 58
Age (continuous) 58
Myasthenia Gravis (yes) 31 14
Recurrence 54 28
Tumor size 5
Type of intervention and surgical approach (n = 217)
  Biopsy only/no resection 16 7
  Sternotomy 136 62
  Thoracotomy 25 12
  Extended approacha 25 12
  VATS/robotic 15 7
Histology (n = 129)
  Squamous cell carcinoma 98 76
  Basaloid 4 3
  Clear cell 4 3
  Lymphoepithelioma like 5 4
  Mucoepidermoid 10 8
  Sarcomatoid 6 5
  Undifferentiated carcinoma 2 1
Resection status (n = 203)
  R0 140 69
  R1 23 11
  R2 24 12
  Biopsy only 16 8
Masaoka-Koga stage (n = 186)
  I 22 12
  IIa 13 7
  IIb 19 10
  III 80 43
  IVa 36 19
  IVb 16 9
Preoperative (primary) therapy (n = 215) 78 36
  CT 53
  Radiotherapy 4
  CT + RT 21
Postoperative (adjuvant) therapy (n = 215) 149 69
  CT 18
  RT 59
  CT + RT 72
aSternotomy + thoracotomy.
CT, chemotherapy; RT, radiotherapy; VATS, video-assisted thoracic surgery.
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Survival rates by the type of surgery (biopsy/no resec-
tion only versus incomplete versus complete resection, Fig. 
2B) suggest a significant survival advantage in case of surgi-
cal resection versus no resection (biopsy only/no resection) 
(p < 0.001). Complete resection was associated with a signifi-
cant increased survival as compared with incomplete resection 
(p < 0.001), and incomplete resection resulted in a significant 
survival advantage versus biopsy only/no resection (p = 0.01)
Survival rates by Masaoka-Koga stage (stages I–II 
versus III versus IV) indicate a nice prognostic stratification 
across the stages (5-year OS: stages I–II, 0.79; stage III, 0.60; 
stage IV, 0.24; p < 0.001) (Fig. 3).
No survival difference was found according to histology 
(squamous cell versus others) (5-year OS: squamous, 0.72; 
others, 0.69; p = 0.2). We further compared survival rates of 
patients with thymic carcinoma with other types of thymic 
tumors in the ESTS database, including B3 thymomas and 
NETT. Five-year survival was similar in thymic carcinomas 
versus NETT (0.61 versus 0.63, p = 0.44), although survival 
was significantly worse in thymic carcinomas versus B3 thy-
momas (0.61 versus 0.82, p < 0.001, Fig. 4).
We analyzed OS rates according to the type of treat-
ment in the following patients groups (Table 2): surgery alone 
(n = 32), preoperative therapy + surgery (n = 34), surgery + 
adjuvant therapy (chemotherapy, radiotherapy, or combined 
chemoradiotherapy) (n = 105), and preoperative therapy + sur-
gery + adjuvant therapy (n = 42). Using as a reference group 
the patients receiving surgery alone, the use of a multidisci-
plinary treatment resulted in a survival advantage which was 
found to be significant in the surgery + postoperative radio-
therapy group (log-rank test, p = 0.02).
Prognostic Predictors
Table 3 shows the analysis of predictors using the two 
end points: OS and FFR.
FIGURE 2.  Cumulative incidence of recurrence (A) and survival by the type of intervention (B) in the patient population. 
FIGURE 3.  Survival curves by Masaoka-Koga staging system 
(stages I–II versus III versus IV).
FIGURE 4.  Survival curves of patients with thymic carci-
noma (n = 215) and B3 thymomas (n = 310) in the ESTS thy-
mic database. ESTS, European Society of Thoracic Surgeons.
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Increased age (p = 0.006; hazard ratio [HR], 1.03; 
95% CI, 1.01–1.04), incomplete resection (p < 0.0001; HR, 
3.03; 95% CI, 1.87–4.91), and advanced stage (Masaoka 
III–IV) (p = 0.02; HR, 2.48; 95% CI, 1.13–5.43) had a nega-
tive impact on OS at multivariable analysis. Administration 
of adjuvant therapy (considered as a whole) was beneficial 
in increasing OS (p = 0.02; HR, 0.55; 95% CI, 0.33–0.92).
When analyzing FFR, no covariate proved to be signifi-
cant at the multivariable analysis, while increased tumor size 
was a significant predictor of recurrence at univariable analy-
sis (p = 0.05; HR, 1.11; 95% CI, 1.00–1.24).
DISCUSSION
The present study based on the ESTS retrospective thy-
mic database represents to our knowledge the largest series of 
patients with thymic carcinoma submitted to surgical resec-
tion to date.
The results of our study indicate that (1) surgical 
resection improves survival over simple biopsy/no resec-
tion; (2) a complete resection is an independent predictor of 
survival; (3) the Masaoka-Koga staging system is an effec-
tive prognostic factor; and (4) the use of a multimodality 
approach including postoperative radiotherapy is effective 
in improving survival.
TABLE 2.  Survival and Log-Rank Test according to Treatments (Surgery Alone as Reference Group)
n p 3 yr (95% CI) 5 yr (95% CI) 10 yr (95% CI)
Surgery alone 32 (as reference) 0.65 (0.43–0.80) 0.61 (0.39–0.77) 0.28 (0.09–0.52).
Surgery + preoperative (primary) therapy 34 0.79 0.63 (0.43–0.77) 0.54 (0.34–0.70) 0.29 (0.10–0.52)
Surgery +postoperative (adjuvant) therapy 105 0.11 0.78 (0.66–0.84) 0.61 (0.50–0.71) 0.43 (0.29–0.56)
  Surgery + CT adjuvant 14 0.94 0.65 (0.26–0.87) 0.50 (0.15–0.77) 0.17 (0.00–0.62)
  Surgery + RT adjuvant 35 0.02 0.79 (0.59–0.90) 0.69 (0.47–0.83) 0.69 (0.47–0.83)
  Surgery + CT and RT adjuvant 56 0.27 0.78 (0.63–0.87) 0.60 (0.44–0.72) 0.37 (0.21–0.53)
Surgery + preoperative and adjuvant therapy 42 0.28 0.75 (0.57–0.86) 0.70 (0.51–0.82) 0.38 (0.17–0.59)
CI, confidence interval; CT, chemotherapy; RT, radiotherapy.
TABLE 3.  Univariate and Multivariate Analysis of Predictors for Overall Survival and Freedom from Recurrence
Univariate Model Multivariate Model
Hazard Ratio SE p
95% CI
Hazard Ratio SE p
95% CI
Lower Upper Lower Upper
Overall survival—multiple imputation for missing data
  Sex (male) 1.03 0.22 0.883 0.67 1.58 0.99 0.23 0.975 0.63 1.55
  Age (continuous, 1 yr) 1.03 0.01 0.001 1.01 1.05 1.03 0.01 0.006 1.01 1.04
  Myasthenia Gravis (yes) 0.56 0.20 0.099 0.28 1.12 0.81 0.30 0.582 0.39 1.69
  Tumor size (continuous, 1 cm) 1.01 0.04 0.709 0.94 1.10 0.99 0.05 0.773 0.89 1.09
  Histology (squamous cell carcinoma vs. other) 1.11 0.34 0.73 0.60 2.04 1.25 0.46 0.54 0.60 2.61
   Other
  Resection status (R0 vs. R1-2) 3.28 0.74 0.000 2.11 5.11 3.03 0.74 0.000 1.87 4.91
  Masaoka-Koga stage (n = 186) I–II vs. III–IV 2.54 0.81 0.004 1.35 4.77 2.48 0.97 0.024 1.13 5.43
  Preoperative (primary) therapy (yes) 1.10 0.25 0.683 0.70 1.71 0.84 0.22 0.510 0.49 1.42
  Postoperative (adjuvant) therapy (yes) 0.64 0.15 0.053 0.41 1.01 0.55 0.15 0.025 0.33 0.93
Freedom from recurrence (end point: recurrence; competing: death)—multiple imputation for missing data
  Sex (male) 0.78 0.30 0.512 0.36 1.66 0.74 0.31 0.471 0.33 1.66
  Age (continuous, 1 yr) 0.99 0.01 0.304 0.96 1.01 0.99 0.01 0.419 0.96 1.02
  Myasthenia Gravis (yes) 0.22 0.21 0.118 0.03 1.46 0.31 0.33 0.265 0.04 2.46
  Tumor size (continuous, 1 cm) 1.11 0.06 0.050 1.00 1.24 1.10 0.08 0.192 0.95 1.26
  Histology (squamous cell carcinoma vs. others) 1.79 0.92 0.26 0.65 4.94 1.81 1.03 0.30 0.58 5.62
   Others
  Masaoka-Koga stage (n = 186) I–II vs. III–IV 1.60 0.81 0.355 0.59 4.36 1.46 0.88 0.536 0.44 4.86
  Preoperative (primary) therapy (yes) 1.84 0.76 0.140 0.82 4.12 1.28 0.63 0.609 0.49 3.34
  Postoperative (adjuvant) therapy (yes) 0.63 0.24 0.234 0.29 1.35 0.78 0.36 0.594 0.32 1.94
CI, confidence interval.
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Thymic carcinomas are rare neoplasms, representing a 
15% to 20% of all thymic tumors.7,8 Contrary to thymomas, 
they show cytologic atypia, lack of an organotypical appear-
ance, and a resemblance to carcinomas occurring in most 
solid organs. Despite the term, thymic carcinomas represent 
a spectrum of tumors, which has been recently classified by 
WHO in 11 subtypes including the NETT.4
Clinically, thymic carcinomas most often present an 
aggressive behavior, are discovered at an advanced stage, and 
have a significantly lower survival than thymomas, with a 
5-year survival of 30% to 60% in most series.  Population-based 
studies indicate an average 16% resection rate in patients with 
thymic carcinoma,9 with a 5-year survival rate of 17% in non-
resectable, advanced stages.10 Until recently, the rarity of these 
tumors has hampered a consensus about prognostic factors 
and optimal treatment strategies.
In the literature, many studies have considered thymic 
carcinomas and thymomas in the same analysis, sometimes 
grouping thymic carcinomas with advanced stages thymo-
mas11,12 based on historical histologic classifications which 
defined thymic carcinomas as “type C” malignant thymomas3,13; 
the denomination of B3 thymomas as  “well-differentiated thy-
mic carcinomas” further contributed to generate some confu-
sion. The latest WHO histologic classification, however, clearly 
pointed out that thymic carcinomas are a distinct category of 
thymic tumors, which should be analyzed separately from 
thymomas. Although in the WHO classification, NETTs are 
included as a subgroup of thymic carcinoma and some stud-
ies included both categories in the analysis,14,15 their unique 
histologic and clinical characteristics, along with the associa-
tion with peculiar endocrinopathies (MEN),16 suggest that they 
should be analyzed as a distinct category, and for this reason, 
they were excluded from the analysis in the present study.
All studies so far on thymic carcinomas have consistently 
demonstrated a significant survival advantage in surgically 
treated patients. Lee et al.17 on a population of 60 patients had 
a 5-year survival rates of 85%, 29%, and 17%, respectively, 
after complete, incomplete resection, and biopsy only. Kondo 
and Monden18 in a population of 154 patients with thymic 
carcinomas reported a 5-year survival of 67% following total 
resection, versus 30% after incomplete resection versus 24% 
when no surgical resection was performed. Weksler et al.19 on 
a large population based on the Surveillance, Epidemiology, 
and End Results (SEER) database found a 5-year survival 
of 58% in case of complete thymic excision versus 26% in 
patients who received no surgery. Our results corroborate 
those obtained on smaller series, with 5-year survival rates of 
80%, 36%, and 19% following complete, incomplete resec-
tion, and biopsy only. Our analysis therefore strongly supports 
surgical resection whenever possible in these tumors. The role 
of incomplete resection in thymic carcinoma has been a mat-
ter of debate in the past. Some authors found that a subtotal 
resection carries a better prognosis than biopsy only,1 whereas 
others17,18 failed to demonstrate any advantage of incomplete 
resection versus no resection at all. Our study indicates that 
an incomplete resection is significantly superior to no resec-
tion and therefore seems worth being carried out if a complete 
resection is not possible.
There is no general agreement about optimal staging sys-
tem for thymic carcinomas. The Masaoka and  Masaoka-Koga 
staging customarily applied in thymomas did not show a simi-
lar efficacy in thymic carcinomas by some authors.9,18,20–22 
These authors found that significant survival differences were 
observed only when Masaoka stages were combined (stages 
I–II versus III–IV or stages I, II, III versus IV)22 or when 
other anatomical factors were taken into account (great ves-
sels invasion).11,20 A TNM-based staging system has also been 
advocated for thymic carcinoma, based on the observation 
that up to 40% of thymic carcinomas present lymphnodal 
metastases which impact on long-term survival,23 although 
the system failed to show significant survival differences in a 
Japanese study,23 possibly due to the small number of patients. 
Weissferdt and Moran8,22 recently simplified the TNM system 
for thymic carcinomas into three-stage categories based on the 
extent of the regional involvement (stages I and II) and meta-
static/distant disease (stage III) and found in their population 
(n = 33) a better prognostic stratification as compared with 
both Masaoka and standard TNM system. On the other hand, 
other series14,17,24 including a large series based on the SEER 
database19 indicate that advanced Masaoka stage is associ-
ated with a decreased survival. In our study, we found a good 
prognostic stratification among Masaoka stages (stages I and II 
were grouped because of a very similar survival). An ongoing 
joint International Association for the Study of Lung Cancer/
ITMIG staging project collecting data from the most important 
thymic databases (ESTS, Japanese Association for Research 
on the Thymus [JART], ITMIG) is currently underway to come 
up with a proposal for a consistent staging system for thymic 
malignancies to be included in the forthcoming 8th edition of 
TNM system of thoracic malignancies. Although awaiting for 
these results, based on our results, we therefore suggest that 
Masaoka staging should be employed in thymic carcinomas.
Thymic carcinomas are customarily approached in a 
multimodality setting. A recent survey from the ESTS about 
optimal management of thymic tumors25 indicates that 52% of 
the interviewed centers used a multimodality approach includ-
ing radio and chemotherapy as adjunct to surgery in case of 
thymic carcinomas. Unfortunately, most of the studies evalu-
ating the role of preoperative (primary) and postoperative 
(adjuvant) therapies following resection of thymic carcinomas 
showed conflicting and not uniform conclusions. Kondo and 
Monden18 found no survival differences in thymic carcinoma 
patients receiving surgery alone versus surgery plus adjuvant 
radiotherapy. Similar results are reported by Lee et al.17 on a 
smaller patient series. Other authors found a marginal benefi-
cial effect of adjuvant radiotherapy.26 Most studies evaluating 
the effect of adjuvant therapies included both thymoma and 
thymic carcinoma. In the present study, the use of a multimo-
dality approach (either preoperative or postoperative or both) 
was found to be superior to surgery alone, with an OS advan-
tage which proved to be significant in the surgery + adjuvant 
radiotherapy group. We are well aware that the different treat-
ment groups were not randomly allocated and a selection bias 
cannot be excluded; nonetheless, our findings support the 
feeling that surgical resection might benefit from the use of a 
postoperative radiation treatment.
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In the present study, tumor size and histology were not 
found to be significant prognostic factors on survival, although 
size was a predictor of recurrence at univariate analysis. In 
thymoma, tumor size was reported as a significant prognostic 
factor in some series,7 although size thresholds, exact mea-
surements (largest diameter versus thee-dimension measures), 
and the independent significance from Masaoka stage are all 
undefined issues which so far have not been elucidated yet. 
As for histology, the rarity of thymic carcinoma certainly rep-
resents a major limitation in the subgroup analysis by histo-
logic subtypes, although some authors found a better survival 
for the squamous type as compared with the other carcinoma 
types.2,26 In the present study, when the squamous cell type 
(n = 98) was compared with all other subtypes (n = 31), no 
survival difference was observed, neither the squamous type 
showed an independent significance on survival or recurrence.
The presence of associated paraneoplastic syndromes is 
a distinct characteristic of thymic tumors. Although MG has 
been found to be present in approximately 30% to 35% of 
the patients with thymoma, the association of MG and thymic 
carcinoma is less often reported and still disputable. Although 
some authors maintain that MG cannot be associated with 
thymic carcinoma,9,27 a not negligible prevalence of MG in 
association with thymic carcinoma has been reported in the 
literature, ranging from 8%14 to 32%28; the variable prevalence 
may possibly be the result of different patients referrals. Our 
14% prevalence is in the range of that reported in the litera-
ture. Our survival analysis indicates that the presence of MG 
had no impact on either survival or recurrence.
The present study presents some strengths and limita-
tions. The main strength is that it represents the largest series 
of patients with thymic carcinoma submitted to surgical resec-
tion to date. A major effort has been undertaken to achieve a 
homogeneous staging system and data information. Another 
strength was the exclusion of NETT from the analysis, which 
in our opinion represent a distinct group of high malignant 
thymic tumors and should therefore be considered separately. 
Among the limitations, unfortunately we did not have suffi-
cient information about the nodal status of the resected thy-
mic carcinomas and the site of distant metastases in stage 
IV patients to draw any conclusion about the impact of these 
covariates on survival. Another limitation includes the lack 
of a central pathology review; it is well known that a great 
interobserver variability has been reported for the WHO his-
tologic classification of thymic malignancies,29 particularly 
between B3 (well-differentiated thymic carcinoma) and thy-
mic carcinoma. To reduce the possible merging of B3 cases 
into the thymic carcinoma population, we compared the sur-
vival curves of the patients with a diagnosis of B3 thymoma 
from the total ESTS database of thymic tumors with the 
patients with thymic carcinoma; the survival difference was 
significant (Fig. 4, p < 0.001), indicating that on average the 
histologic allocation was correct. Another limitation results 
from the collection of data from centers with a different geo-
graphic location, expertise, and volume activity, which might 
results in a heterogeneity of treatment strategies. Finally, the 
information about recurrence status, resection status, and 
perioperative treatments was not complete, with a loss of 
statistical power particularly in the recurrence analysis and an 
anticipated underestimation of the CIR.
In conclusion, the results of the present retrospective 
study on a large population of patients with thymic carcinoma 
suggest that surgery is indicated whenever possible; a com-
plete resection and an early Masaoka stage are predictors of 
improved survival. Our results also indicate that postoperative 
radiotherapy is beneficial in improving survival.
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